Genmab A (GMAB) Change in Cash (2018 - 2026)
Genmab A's (GMAB) quarterly Change in Cash came in at -$183.0 million in Q1 2026, down 179.22% YoY from $231.0 million in Q1 2025, and down 148.93% on a QoQ basis from $374.0 million in Q3 2025.
Genmab A (GMAB) Change in Cash (2018 - 2026) Analysis & Trends
Genmab A (GMAB) has 7 years of Change in Cash data on file, last reported at -$183.0 million in Q1 2026.
- Quarterly Change in Cash fell 179.22% year-over-year to -$183.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $335.0 million (up 135.75% YoY) and the FY2025 annual result came in at $332.0 million, up 137.43% from the prior year.
- Change in Cash retreated to -$183.0 million in Q1 2026, from $374.0 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $1.3 billion in Q3 2024 to a low of -$3.5 billion in Q4 2023.
- A 4-year average of -$488.4 million and a median of -$87.0 million in 2025 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2025 — Change in Cash jumped 403.95% — and 2026, when it plunged 179.22%.
- Tracing GMAB's Change in Cash over 4 years: stood at -$3.5 billion in 2023, then soared by 74.56% to -$887.0 million in 2024, then jumped by 142.16% to $374.0 million in 2025, then sank by 148.93% to -$183.0 million in 2026.
- The last three Change in Cash figures came in at -$183.0 million (Q1 2026), $374.0 million (Q3 2025), and -$87.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 427.25 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.97 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.94 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | -22.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.00 Mn |
| Mar 31, 2026 | -183.00 Mn |
| Sep 30, 2025 | 374.00 Mn |
| Jun 30, 2025 | -87.00 Mn |
| Mar 31, 2025 | 231.00 Mn |
| Dec 31, 2024 | -887.00 Mn |
| Sep 30, 2024 | 1.29 Bn |
| Jun 30, 2024 | -1.57 Bn |
| Mar 31, 2024 | -76.00 Mn |
| Dec 31, 2023 | -3.49 Bn |
| Sep 30, 2020 | 4,687.00 |
| Dec 31, 2019 | 4,166.00 |
| Sep 30, 2019 | 4.17 Bn |
| Dec 31, 2018 | -175.51 Mn |